

The T@blet

News from the Medicines Management Team

Issue 8 October 2019

CONTENTS

Priority information	1
SSRI's SPC updates	1
OTC – Focus on Sun cream	2
Silver Dressings	3
Information	4
Capsaicin cream shortage	4
Prescribing Guidance: Drugs used in the treatment of Erectile Dysfunction (ED)	4
MMT Staffing Update	4
APC prescribing Committee September UPDATE	4
Emerade alert	5
Montelukast alert	5

PRIORITY INFORMATION

SSRI'S SPC UPDATES

Revised SPCs: Efexor XL (venlafaxine) products

SPC has been updated with the addition of a warning regarding sexual dysfunction after drug withdrawal.

Revised SPCs: Lustral (sertraline) 50 and 100mg film coated tablets

SPC updated to warn that SSRIs may cause symptoms of sexual dysfunction, with reports of long-lasting sexual dysfunction where the symptoms have continued despite treatment discontinuation. Maculopathy has also been added as adverse effect of unknown frequency.

For general enquiries please email: donccg.medicinesmanagementadmin@nhs.net

For practice pharmacist queries please email: donccg.rxline@nhs.net

OTC – FOCUS ON SUN CREAM

Prescribing increased month on month in the below areas. In July this year we spent £10K more on OTC products than we did in July last year. Prescribing for migraine, burns and sun cream increased significantly. This is opposite to the NHSE trend.

OTC Condition	June Patients	July Patients	% Increase
Acute Sore Throat	352	378	7.39%
Cradle cap (seborrhoeic dermatitis in infants)	208	223	7.21%
Diarrhoea (Adults)	471	494	4.88%
Dry Eyes/Sore tired Eyes	2072.5	2116	2.10%
Earwax	114	154	35.09%
Excessive sweating (Hyperhidrosis)	21.5	29	34.88%
Indigestion and Heartburn	3152	3214.5	1.98%
Infant Colic	18	20	11.11%
Infrequent Constipation	706.6	708.2	0.23%
Infrequent Migraine	18.4	54.4	195.65%
Insect bites and stings	22	28	27.27%
Mild Acne	52	64	23.08%
Mild Dry Skin/Sunburn	1160.8	1232.6	6.19%
Mild contact dermatitis	218	253	16.06%
Mild to Moderate Hay fever/Allergic Rhinitis	5611.2	5943.2	5.92%
Minor burns and scalds	3.2	5.6	75.00%
Minor conditions associated with pain, discomfort and/fever. (e.g. aches and sprains, headache, peri	3025.8	3099.8	2.45%
Nappy Rash	84.8	96.8	14.15%
Prevention of dental caries	107.2	108.8	1.49%
Ringworm/Athletes foot	872	971.2	11.38%
Sun Protection	57.6	80.1	39.06%
Threadworms	32.8	36.8	12.20%
Travel Sickness	548.8	620	12.97%
Warts and Verrucae	84	90	7.14%

Sun cream in particular should only be prescribed, irrespective of the OTC drive, for abnormal cutaneous photosensitivity resulting from genetic disorders or photodermatoses, including vitiligo and those resulting from radiotherapy; chronic or recurrent herpes simplex labialis¹. **Prescribing for other indications should not occur on FP10.** See this [useful document](#).

The only sun creams that should be prescribed for the above indications are;

Anthelios® XL Melt-in cream (UVA ,UVB protection; UVB-SPF 50+)
 Sensesense® Ultra Lotion (UVA ,UVB protection; UVB-SPF 50)
 Uvistat® Cream (UVA ,UVB protection; UVB-SPF 30)
 Uvistat® Cream (UVA ,UVB protection; UVB-SPF 50)
 Uvistat® Lipscreen (UVA ,UVB protection; UVB-SPF 50)

Discontinue any prescribing for:

- Sun creams other than the five products listed above as these are the only suncream products

For general enquiries please email: donccg.medicinesmanagementadmin@nhs.net

For practice pharmacist queries please email: donccg.rxline@nhs.net

which meet ACBS criteria.

- Patients who do not meet ACBS criteria. Advise these patients to purchase an appropriate sun cream over-the-counter (OTC) instead. Further information on sun safety for patients is available from the British Association for Dermatologists and NHS Choices.

In particular the prescribing of daily face cream (£688 in July) and anti-aging cream (£47 a pot) may be areas for review:

Sunsense_Daily Face Crm Spf 50+


CONISBROUGH GROUP PRACTICE (C86024)
 CONISBROUGH MEDICAL PRACTICE (C86625)
 DENABY MEDICAL PRACTICE (C86616)
 DUNSVILLE MEDICAL CENTRE (C86611)
 EDLINGTON HEALTH CENTRE PRACTICE (C86026)
 FIELD ROAD SURGERY (C86037)
 GREAT NORTH MEDICAL GROUP (C86001)
 REGENT SQUARE GROUP PRACTICE (C86006)
 ST VINCENT MEDICAL CENTRE (C86029)
 ST.JOHNS GROUP PRACTICE (C86020)
 THE BURNS PRACTICE (C86007)
 THE LAKESIDE PRACTICE (C86016)
 THE MAYFLOWER MEDICAL PRACTICE (C86009)
 THE NEW SURGERY (C86034)
 THE SANDRINGHAM PRACTICE (C86022)
 THE TICKHILL & COLLIERY MEDICAL PRACTICE (C86013)
 THORNE MOOR MEDICAL PRACTICE (C86614)

Ultrasun_Anti-Aging Face Crm SPF 30

MEXBOROUGH HEALTH CENTRE (C86005)

SILVER DRESSINGS

These have been classed as RED - specialist prescribing only by the CCG. NICE states: "There is at present no robust clinical- or cost-effectiveness evidence to support the use of antimicrobial dressings (for example, silver, iodine or honey) over non-medicated dressings for preventing or treating chronic wounds. Indiscriminate use should be discouraged because of concerns over bacterial resistance and toxicity". Doncaster is the 2nd highest prescriber in England of silver dressings as a % of all its dressings. Below are the top 3:



For general enquiries please email: donccg.medicinesmanagementadmin@nhs.net

For practice pharmacist queries please email: donccg.rxline@nhs.net

Please [click here](#) to see your practice's position. As part of the RED product support the MMT can assist you to repatriate these patients (if continuance of silver dressings is indeed necessary) to the specialist service. [RED product letters](#) can be found on the APC pages of the MMT website

INFORMATION

CAPSAICIN CREAM SHORTAGE

Teva, the sole supplier of Zacin 0.025% cream and Axsain 0.075% cream have announced that they will be out of stock of both Capsaicin creams until November 2019 at the earliest. Guidance on alternative agents and management options is available in the shortage of supply memo: ow.ly/cXeZ30pwE7A

Prescribing Guidance: Drugs used in the treatment of Erectile Dysfunction (ED)

The updated prescribing guidance for drugs used in the treatment of Erectile Dysfunction has been uploaded to the Medicines Management Website. This includes an updated pathway and use of tadalafil by GP practices.

To access the document [Click Here](#)

MMT STAFFING UPDATE

We are pleased to announce that a new pharmacy technician is joining our practice support team to assist practices with work on the CCG QIPP plans. Amanda Hemmings has previously worked with Rotherham CCG. Existing staff members will introduce her to the practices she is due to support.

We also welcome Rachel Hubbard, who is a GP at Bentley Village Surgery joins us on a sessional basis as a GP prescribing advisor to support commissioning decisions and pathway development.

APC PRESCRIBING COMMITTEE SEPTEMBER UPDATE

Eculizumab (Soliris) used to treat Paroxysmal nocturnal haemoglobinuria, Atypical hemolytic uremic syndrome and new indication of Neuromyelitis optica spectrum disorder has been categorised as **Red 1,2,8**

Valproate Semi-Sodium (Belvo) used for manic episode in bipolar disorder when lithium is contraindicated or not tolerated has been classified as **Red 1**

Dupilumab (Dupixent) used for Asthma has been classified as **Grey 2**

Dupilumab (Dupixent) used for Atopic Dermatitis has been classified as **Red 1,2,8**

Benralizumab (Fasenra) used for severe eosinophilic asthma has been classified as **Red 1,2,8**

For general enquiries please email: donccg.medicinesmanagementadmin@nhs.net

For practice pharmacist queries please email: donccg.rxline@nhs.net

Lorlatinib (Lorviqua) used for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer has been classified as **Red 1,2**

Antacid and Oxetacaine is to be discussed further at the next APC once more information is obtained.

Dapagliflozin (Forxiga) used for Diabetes Mellitus Type 1 has been classified as **Amber G** (with link to NICE guidance)

Silver dressings were classified as **Red 1,2**

EMERADE ALERT

[Emerade pens – patients reminded to carry 2 pens at all times](#)

Patients who carry Emerade auto-injector pens for the emergency treatment of severe acute allergic reactions (anaphylaxis) to foods, medicines or insect stings are being reminded of existing advice to carry 2, in-date pens with them – at all times.

MONTELUKAST ALERT

Prescribers should be alert for neuropsychiatric reactions in patients taking montelukast and carefully consider the benefits and risks of continuing treatment if they occur.

<https://www.gov.uk/drug-safety-update/montelukast-singulair-reminder-of-the-risk-of-neuropsychiatric-reactions>

For general enquiries please email: donccg.medicinesmanagementadmin@nhs.net

For practice pharmacist queries please email: donccg.rxline@nhs.net